Generic drug of the therapeutic class: Dermatology
active ingredients: Calcipotriol, Betamethasone
laboratory: Leo Pharmaceutical Ltd
Box of 1 bottle of 60 g
Topical treatment of scalp psoriasis in adults.
Topical treatment of mild-to-moderate vulvar psoriasis plaques outside the scalp in adults.
Dosage DAIVOBET 50 micrograms / 0.5 mg / g Gel Box of 1 Bottle of 60 g
Daivobet gel should be applied once a day to the lesions. The recommended duration of treatment is 4 weeks for the scalp and 8 weeks outside the scalp. If it is necessary to continue or resume treatment after this period, treatment should be continued after medical advice and under regular medical supervision.
When using products containing calcipotriol, the maximum daily dose should not exceed 15 g. Body surface area treated with products containing calcipotriol should not exceed 30% (see Warnings and Precautions ) section.
If used on the scalp
All areas of the scalp affected can be treated with Daivobet gel. Usually, a quantity between 1 g and 4 g per day is sufficient to treat the scalp (4 g correspond to a teaspoon).
Renal and hepatic insufficiency
The safety and effectiveness of Daivobet gel in patients with severe renal impairment or severe liver disorders have not been evaluated.
The safety and effectiveness of Daivobet gel in children under 18 years of age have not been established. No data available.
The vial should be shaken before use and Daivobet gel applied to the lesions. Daivobet gel should not be applied directly to the face or eyes. Wash hands after use. To have an optimal effect, it is not recommended to take a shower or a bath, or to wash your hair if applied on the scalp, immediately after the application of Daivobet gel. Daivobet gel should stay on the skin overnight or during the day.
Known hypersensitivity to active ingredients or to any of the excipients.
Daivobet gel is contraindicated in case of erythrodermic, exfoliating and pustular psoriasis.
Due to the presence of calcipotriol, Daivobet gel is contraindicated in patients with a history of calcium metabolic disorders.
Due to the presence of corticosteroids, Daivobet gel is contraindicated in the following cases: skin lesions of viral origin (eg herpes or varicella), skin infections of fungal or bacterial origin, parasitic infections, cutaneous in connection with tuberculosis or syphilis, perioral dermatitis, skin atrophy, stretch marks, fragility of the cutaneous venous network, ichthyosis, acne vulgaris, rosacea, rosacea, ulcers, wounds, perianal and genital pruritus.
Daivobet side effects
The clinical trial program of Daivobet Gel has so far included more than 4, 700 patients, of whom more than 2, 100 have been treated with Daivobet Gel. Approximately 8% of patients treated with Daivobet gel experienced a non-serious adverse reaction.
These reactions are usually benign and cover mainly various skin reactions, pruritus being the most common.
Based on data from clinical trials and post-marketing use the following side effects are listed for Daivobet gel.
Adverse reactions are classified according to MedDRA System Organ Class, and individual adverse reactions are listed beginning with the most frequently reported. In each grouping of frequencies, adverse reactions are listed by decreasing severity.
The following terminologies have been used to classify adverse event frequencies:
Very common ≥1 / 10
Frequent ≥1 / 100 and <1/10
Uncommon ≥1 / 1, 000 and <1/100
Rare ≥1 / 10, 000 and <1/1000
Very rare <1/10 000
Not known (can not be evaluated with available data)
Skin and subcutaneous tissue disorders
Exacerbation of psoriasis
Burning sensation of the skin
Skin pain or irritation
The following adverse reactions are considered in relation to the pharmacological classes of calcipotriol and betamethasone, respectively:
Side effects include application site reactions, pruritus, skin irritation, burning and stinging sensation, dry skin, erythema, rash, dermatitis, eczema, worsening of psoriasis, photosensitivity, and hypersensitivity reactions including rare cases of angioedema and edema of the face.
Systemic effects after topical application may occur very rarely and cause hypercalcemia or hypercalciuria (see Warnings and Precautions section ).
Betamethasone (as dipropionate)
Local reactions may occur after topical use, especially during prolonged exposure, including skin atrophy, telangiectasia, stretch marks, folliculitis, hypertrichosis, perioral dermatitis, contact dermatitis, depigmentation, and colloid milium. When treating psoriasis, there may be a risk of generalized pustular psoriasis.
Systemic effects after topical application of corticosteroids are rare in adults, however, they can be severe. Braking of the hypothalamic-pituitary axis, cataract, infections, an impact on the control of metabolism of diabetes mellitus and an increase in intraocular pressure can occur, especially after prolonged treatment. Systemic effects occur more frequently when applied under occlusion (plastic, skin folds), when applied over large areas and during long-term treatment (see section Warnings and precautions for use). ).